Supported by R01EY011289 and R01EY034080 (JGF) and DFG project 508075009 (SBP).
Presented at the 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology, Seattle, WA, USA, May 8th, 2024.
Disclosure: J. Won, None; A. Yaghy, Beacon Therapeutics (C), Boston Image Reading Center (C); S.B. Ploner, VISTA (P); S. Kaiser, Ocuphire Pharma (C); J.M. Girgis, None; Y. Hwang, None; M.U. Jamil, None; A. Maier, None; N.K. Waheed, Zeiss (F), Topcon (C, F), Nidek (C, F), Regeneron (F), Complement Therapeutics (C), OliX Pharmaceuticals (C), Iolyx Pharmaceuticals (C, I), Boehringer Ingelheim (C), Jansen (C), Aavantgarde Bio (C), Samsung Bioepis (C), Alkeus Pharmaceuticals (C), Ocular Therapeutix (C, E), Valitor (I), Ocudyne (I), Beacon Therapeutics (I); J.G. Fujimoto, Optovue (I, P), Topcon (F), VISTA (P)